Long-term follow-up of people with chronic hepatitis B treated with AHB-137
Follows adults with chronic hepatitis B after AHB-137 injection treatment.
Plain-language title generated from the registry record
Registry title: Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
Key facts
- Where
- Beijing, Changchun, Changhou, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Kunming, Lanzhou, Liuzhou, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Taiyuan, Wuhan, Xi’an, Xiamen, Zhengzhou, Zhenjiang, and Zunyi, ChinaSee the 28 sites
Where in China
- BeijingBeijing, ChinaNot yet recruiting
- ChangchunChangchun, ChinaTaking people
- ChanghouChanghou, ChinaTaking people
- ChangshaChangsha, ChinaNot yet recruiting
- ChengduChengdu, ChinaNot yet recruiting
- ChongqingChongqing, ChinaTaking people
- FoshanFoshan, ChinaNot yet recruiting
- FuzhouFuzhou, ChinaTaking people
- GuangzhouGuangzhou, ChinaTaking people
- HaikouHaikou, ChinaNot yet recruiting
- HangzhouHangzhou, ChinaTaking people
- HefeiHefei, ChinaNot yet recruiting
- KunmingKunming, ChinaNot yet recruiting
- LanzhouLanzhou, ChinaNot yet recruiting
- LiuzhouLiuzhou, ChinaNot yet recruiting
- NanchangNanchang, ChinaNot yet recruiting
- NanjingNanjing, ChinaNot yet recruiting
- NanningNanning, ChinaNot yet recruiting
- ShanghaiShanghai, ChinaNot yet recruiting
- ShenyangShenyang, ChinaNot yet recruiting
- ShenzhenShenzhen, ChinaNot yet recruiting
- TaiyuanTaiyuan, ChinaNot yet recruiting
- WuhanWuhan, ChinaNot yet recruiting
- Xi’anXi’an, ChinaNot yet recruiting
- XiamenXiamen, ChinaNot yet recruiting
- ZhengzhouZhengzhou, ChinaNot yet recruiting
- ZhenjiangZhenjiang, ChinaTaking people
- ZunyiZunyi, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ausper Biopharma Co., Ltd.
- Trial code
- NCT07146100
- Record updated
- 18 August 2026
- Original description
This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.Read full original descriptionShow less
Prospective, Open-label, Multicenter Long-term Follow-up Study to Evaluate the Durability of Virologic Response in Participants With Chronic Hepatitis B Previously Treated With AHB-137 Injection
This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.
Inclusion: Capable of giving informed consent; Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study.
Exclusion: Participants who have/or are currently participating in another interventional clinical study since completing their treatment with AHB-137; Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.